Advertisement
Screener

Theravance Biopharma, Inc. (TBPH) Cash Flow Breakdown

2.8 / 5 stars · 68/120 Roast Me

Theravance Biopharma, Inc. Cash Flow Breakdown

Cash flow breakdown shows where Theravance Biopharma, Inc.'s cash came from and where it went: from running the business, from investing (buying or selling equipment, companies and investments) and from financing (borrowing, paying back loans, buying back shares, paying dividends). One row per year or quarter. A minus sign means cash went out. Financing is shown line by line: buybacks, dividends, debt paid back, new debt and the rest. All amounts are the filed figures for that period.

  • Fiscal year ended 2025-12-31: from running the business, $238.54M came in.
  • Fiscal year ended 2025-12-31: from investing, $105.28M went out.
  • Fiscal year ended 2025-12-31: from financing, $3.25M went out.
  • Fiscal year ended 2025-12-31: change in cash, $130.01M came in.

A minus sign means cash went out. * = worked out from the filed year-to-date figures (hover to see how); greyed = already counted inside another line.

Each year (12 month)

Fiscal year endRunning the businessFrom investingBuybacksNew debtStaff share taxNew shares soldOtherNot split outChange in cash
2025-12-31$238.54M-$105.28M-$4.03M$20.00K$766.00K*$130.01M
2024-12-31-$11.54M$12.28M-$445.00K*-$2.66M$99.00K-$1.75M
2023-12-31-$27.00M-$32.70M-$197.05M-$2.50M$618.00K-$258.63M
2022-12-31-$186.99M$1.15B-$128.83M-$3.45M$802.00K-$627.33M*$208.21M
2021-12-31-$207.86M$124.49M-$9.06M$108.18M-$7.26M*$8.50M
2020-12-31-$250.40M$10.72M$380.00M-$9.75M$139.91M-$247.08M*$23.40M
2019-12-31-$238.20M-$83.05M-$3.17M$3.14M$1.32M*-$319.96M
2018-12-31-$112.87M$176.71M-$9.81M$1.39M$233.61M*$289.04M
2017-12-31-$201.05M-$56.33M-$8.56M$6.24M$3.98M*-$255.73M
2016-12-31-$98.99M-$148.24M$222.50M-$3.87M$253.03M$21.00K$7.55M*$232.00M
2015-12-31-$168.86M$111.04M$0.00-$756.00K$79.02M-$75.00K$3.12M*$23.49M
2014-12-31-$175.16M-$106.25M$0.00-$178.00K$0.00$282.00K$370.52M*
2013-12-31-$120.96M-$2.63M$0.00$0.00$0.00$123.59M*
2012-12-31-$119.11M-$2.43M$0.00$0.00$121.54M*

Each quarter (3 month)

Quarter endRunning the businessFrom investingBuybacksNew debtStaff share taxNew shares soldOtherNot split outChange in cash
2026-06-30-$6.96M*-$60.40M*-$2.10M*$1.14M*
2026-03-31$73.28M$52.59M-$5.82M$241.00K$120.30M
2025-12-31-$6.06M*$588.00K*-$1.98M*$0.00*
2025-09-30-$6.51M*-$100.25M*-$678.00K*$0.00*
2025-06-30$208.07M*-$36.26M*-$503.00K*$0.00*
2025-03-31$43.04M$30.63M-$874.00K$20.00K$72.82M
2024-12-31-$902.00K*$15.69M*$0.00*-$528.00K*$30.00K*
2024-09-30-$5.20M*-$17.40M*$0.00*-$397.00K*$25.00K*
2024-06-30-$4.42M*-$3.03M*$0.00*-$463.00K*
2024-03-31-$1.02M$17.03M-$445.00K-$1.27M$14.29M
2023-12-31-$854.00K*-$677.00K*-$30.26M*-$518.00K*$173.00K*
2023-09-30-$2.49M*-$21.00K*-$30.89M*-$512.00K*-$1.00K*
2023-06-30-$12.44M*$11.05M*-$80.54M*-$583.00K*
2023-03-31-$11.22M-$43.05M-$55.35M-$887.00K-$110.51M
2022-12-31-$124.06M*$39.16M*-$34.79M*-$993.00K*$314.00K*
2022-09-30-$22.14M*$1.08B*-$662.00K*$1.00K*-$721.37M*
2022-06-30-$14.73M*$7.51M*-$347.00K*
2022-03-31-$26.07M$31.92M-$1.45M$4.41M
2021-12-31-$42.43M*$10.82M*-$455.00K*$0.00*
2021-09-30-$45.45M*-$35.79M*-$2.29M*$0.00*
2021-06-30-$50.11M*$35.77M*-$727.00K*$2.00K*$106.01M*
2021-03-31-$69.86M$113.70M-$5.59M$3.00K-$5.70M*$32.54M
2020-12-31-$64.92M*$52.37M*$0.00*-$814.00K*$0.00*$1.56M*
2020-09-30-$77.03M*$66.54M*$0.00*-$987.00K*$0.00*
2020-06-30-$53.35M*-$176.59M*$0.00*-$1.14M*$0.00*$3.02M*
2020-03-31-$55.10M$68.40M$380.00M-$6.80M$139.91M-$251.68M*$274.73M
2019-12-31-$64.35M*$14.06M*-$430.00K*$169.00K*-$1.28M*
2019-09-30-$44.62M*-$23.66M*-$562.00K*$428.00K*
2019-06-30-$48.03M*-$1.30M*-$494.00K*$2.29M*$2.60M*
2019-03-31-$81.19M-$72.16M-$1.69M$254.00K-$154.79M
2018-12-31-$52.18M*$99.39M*-$1.35M*$87.00K*$230.87M*
2018-09-30-$48.98M*$46.65M*-$1.55M*$1.23M*
2018-06-30-$61.54M*$41.96M*-$5.19M*$46.00K*$2.74M*
2018-03-31$49.83M-$11.29M-$1.72M$35.00K$36.85M
2017-12-31-$44.20M*$41.25M*-$1.24M*$543.00K*-$2.32M*
2017-09-30-$62.30M*$14.76M*-$1.16M*$373.00K*-$48.33M*
2017-06-30-$44.52M*$11.18M*-$2.13M*$2.50M*$2.66M*
2017-03-31-$50.03M-$123.52M-$4.03M$2.82M
2016-12-31-$28.11M*-$46.20M*-$1.02M*$107.79M*$21.00K*$225.67M*$258.14M*
2016-09-30-$12.43M*-$49.84M*-$626.00K*$17.00K*$0.00*-$61.79M*
2016-06-30-$32.13M*-$68.58M*-$442.00K*$117.42M*$0.00*$3.29M*
2016-03-31-$26.31M$16.39M-$1.78M$27.80M$0.00
2015-12-31-$33.75M*-$34.50M*-$756.00K*$51.76M*-$281.00K*$3.12M*
2015-09-30-$31.98M*$62.09M*$0.00*-$48.00K*-$34.00K*
2015-06-30-$46.61M*$41.30M*$100.00K*$1.56M*-$151.00K*
2015-03-31-$56.51M$42.15M-$100.00K$25.75M$391.00K
2014-12-31-$42.54M*$9.68M*$0.00*-$111.00K*
2014-09-30-$36.38M*-$109.86M*$0.00*$393.00K*
2014-06-30-$51.44M*-$4.46M*$0.00*$324.10M*
2014-03-31-$44.80M-$1.62M$0.00$0.00$46.42M*
2013-12-31-$35.19M*-$1.07M*$0.00*$36.25M*
2013-09-30-$32.94M*-$237.00K*$33.17M*
2013-06-30-$24.34M*-$691.00K*$25.04M*
2013-03-31-$28.49M-$640.00K$29.13M*

Similar stocks

Stock NameCountryMarket CapPE Ratio
Cryoport, Inc. (CYRX)United States$0.881B-21.29
RIGEL PHARMACEUTICALS INC (RIGL)United States$0.893B2.25
Apnimed, Inc. (APMD)United States$0.899B
ARDELYX, INC. (ARDX)United States$0.857B-22.86
Avalo Therapeutics, Inc. (AVTX)United States$0.842B-9.74
Immix Biopharma, Inc. (IMMX)United States$0.837B-18.44
Jade Biosciences, Inc. (JBIO)United States$0.936B-9.21
Obsidian Therapeutics, Inc. (OBX)United States$0.829B
LEXICON PHARMACEUTICALS, INC. (LXRX)United States$0.823B-17.48
GYRE THERAPEUTICS, INC. (GYRE)United States$0.818B-24.71